EMPAGLIFLOZIN RENAL SAFETY IN NORMOGLYCEMIC RATS WITH HEART FAILURE
https://doi.org/10.24884/1561-6274-2018-22-1-83-90
Abstract
The aim: to evaluate the effect of the sodium-glucose cotransporter SGLT-2 inhibitor – empagliflozin on the kidney in nondiabetic Wistar rats with experimental heart failure (HF).
Material and methods. Chronic HF was induced by ligation the left coronary artery. Animals with HF in the first group (n=11) received empagliflozin (Jardiance®, Boehringer Ingelheim) orally (1 mg / kg/day) for 1 month. In the second group of rats with HF (n = 10) the drug is not administered. Concentrations and daily urinary excretion of glucose, protein and albumin were measured. The relative level of microRNA-21 urinary expression was established. Morphological examination of kidney tissue was performed using light microscopy.
Results. The administration of empagliflozin to experimental animals resulted in regularly higher values of diuresis, glucose concentration in urine and its daily excretion. There were no significant differences in levels of albuminuria and proteinuria or miRNA-21 expression in urine in groups with and without empagliflozin. The animals receiving the drug showed a slightly less pronounced damage to the cells of the tubular epithelium compared to rats with only heart failure.
Conclusion. The data obtained, at least confirm the renal safety of long-term empagliflozin administration even under conditions of high risk.About the Authors
S. V. Okovity`i`
Saint Petersburg state chemical pharmaceutical academy
Russian Federation
Russian Federation
Sergey V. Okovityi - MD, PhD, DMedSci, Prpf., department of pharmacology and clinical pharmacology, head.
197022 St-Petersburg, Prof. Popova st., 14, lit.A, (812) 234-13-29
O. N. Beresneva
First Pavlov St.-Petersburg State Medical University Institute of Nephrology, Nephrology research institute of scientific clinical research centre
Russian Federation
Russian Federation
Olga N. Beresneva – PhD, senior researcher, Nephrology Laboratory of Clinical Physiology of the Kidney.
197022 St-Petersburg , L.Tolstoy st., 17, build. 54, (812)346-39-26
M. M. Parastaeva
First Pavlov St.-Petersburg State Medical University Institute of Nephrology, Nephrology research institute of scientific clinical research centre
Russian Federation
Russian Federation
Marina M. Parastaeva – PhD, senior researcher, Laboratory of Clinical Physiology of the Kidney.
197022 St-Petersburg , L.Tolstoy st., 17, build. 54, (812)346-39-26
G. T. Ivanova
Pavlov physiology institute Russian academy of science
Russian Federation
Russian Federation
Galina T. Ivanova - PhD, senior researcher, Laboratory of Experimental and Clinical Cardiology.
199034 St-Petersburg, Makarov emb. 6, (812) 3280701
D. Yu. Ivkin
St. Petersburg state chemical-pharmaceutical academy, Center of experimental pharmacology
Russian Federation
Russian Federation
Dmitry Y. Ivkin – PhD, director.
199034, St-Petersburg, Prof. Popova st., 14, lit. A, (812) 234-13-29
A. S. Ivkina
St. Petersburg State chemical-pharmaceutical academy, Center of experimental pharmacology
Russian Federation
Russian Federation
Arina S. Ivkina – researcher, pharmacological research laboratory.
197022 St-Petersburg, Prof. Popova st., 14, lit.A, (812) 234-13-29
V. G. Sipovskii
First Pavlov St.-Petersburg State Medical University Institute of Nephrology, Nephrology research institute of scientific clinical research centre
Russian Federation
Russian Federation
Evdokia O. Bogdanova – researcher, Laboratory of Biochemical Homeostasis.
197022 St-Petersburg, L.Tolstoy st., 17, build. 54, (812) 338-69-01
M. I. Zaraiyskii`
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Mikhail I. Zaraiski - MD, PhD, DMedSci., Prof., Department of clinical laboratory diagnostics with a course of molecular medicine.
197022 St-Petersburg, L. Tolstoy st., 6/8, build. 10, (812) 346-39-26
A. A. Karpov
Federal medical research center VA Almazov
Russian Federation
Russian Federation
Andrey A. Karpov - junior researcher.
197022 St-Petersburg, Parkhomenko st, 15, (812) 702-51-68
А. G. Kucher
First Pavlov St.-Petersburg State Medical University, Research and clinical research cente
Russian Federation
Russian Federation
Anatoly G. Kucher - MD, PhD, DMedSci., Prof., vice-director.
197022 St-Petersburg, L.Tolstoy st., 17, build. 54, +7921 4211817
E. O. Bogdanova
Nephrology research institute of scientific clinical research centre
Russian Federation
Russian Federation
Evdokia O. Bogdanova – researcher, Laboratory of Biochemical Homeostasis.
197022 St-Petersburg, L.Tolstoy st., 17, build. 54, (812) 338-69-01
E. B. Sipovskaya
First Pavlov St.-Petersburg State Medical University Institute of Nephrology, Nephrology research institute of scientific clinical research centre
Russian Federation
Russian Federation
Elena B. Sipovski – researcher, Laboratory Clinical Morphology and Immunology, researcher.
197022 St-Petersburg, L.Tolstoy st., 17, build. 54, (812)3386932
A. N. Kulikov
First Pavlov St.-Petersburg State Medical University, Research and clinical research center
Russian Federation
Russian Federation
Prof. Aleksandr N. Kulikov - MD, PhD, DMedSci., Department of clinical physiology and functional diagnostics, head.
197022 St-Petersburg , L.Tolstoy st., 6-8, (812) 338-71-23
I. G. Kayukov
First Pavlov St.-Petersburg State Medical University, Institute of Nephrology
Russian Federation
Russian Federation
Ivan G. Kayukov - MD, PhD, DMedSci., Prof., Laboratory of Clinical Physiology of the Kidney, head.
197022 St-Petersburg, L. Tolstoy st. 17, build. 54, (812) 346-39-26
References
1. Куликов АН, Береснева ОН, Парастаева ММ и др. Влияние эмпаглифлозина на состояние почек у нормогликемических крыс с сердечной недостаточностью. Нефрология 2017; 21(2): 83-92 [Kulikov AN, Beresneva ON, Parastaeva MM i dr. Vliyanie empagliflozina na sostoyanie pochek u normoglikemicheskih kryis s serdechnoy nedostatochnostyu. Nefrologiya 2017; 21(2): 83-92]
2. Куликов АН, Оковитый СВ, Ивкин ДЮ и др. Эффекты эмпаглифлозина при экспериментальной модели хронической сердечной недостаточности у крыс с нормогликемией. Сердечная недостаточность 2016; 17(6):454-460 [Kulikov AN,Okovityiy SV, Ivkin DYu. Effektyi empagliflozina pri eksperimentalnoy modeli hronicheskoy serdechnoy nedostatochnosti u kryis s normoglikemiey. Serdechnaya nedostatochnost 2016; 17(6):454-460]
3. Смирнов АВ, Добронравов ВА, Кисина АА и др. Клинические рекомендации по диагностике и лечению диабетической нефропатии. Нефрология 2015;19(1): 67-77 [Smirnov AV, Dobronravov VA, Kisina AA i dr. Klinicheskie rekomendacii po diagnostike i lecheniyu diabeticheskoj nefropatii. Nefrologiya 2015;19(1): 67-77]
4. Mima A. Diabetic nephropathy: protective factors and a new therapeutic paradigm. J Diabetes Complications 2013;27(5):526–530
5. Hoshino J, Mise K, Ueno T et al. A pathological scoring system to predict renal outcome in diabetic nephropathy. Am J Nephrol 2015;41(4-5):337–344
6. Patschan D, Müller GA. Acute kidney Injury in diabetes mellitus. Int J Nephrol 2016; 2016:6232909
7. Tang SC, Chan GC, Lai KN. Recent advances in managing and understanding diabetic nephropathy. F1000Res 2016 May 31;5. pii: F1000 Faculty Rev-1044. doi: 10.12688/f1000research.7693.1
8. Vallianou NG, Geladari E, Kazazis CE. SGLT-2 inhibitors: Their pleiotropic properties. Diabetes Metab Syndr 2016; pii: S1871-4021(16)30226-0. doi: 10.1016/j.dsx.2016.12.003. [Epub ahead of print]
9. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 2017; 60(2):215-225
10. Бабенко АЮ, Байрашева ВК. Диабетическая нефропатия. Зависит ли ренопротекция от выбора сахароснижающей терапии. Мед совет 2015; (7): 32-43 [Babenko AYU, Bajrasheva VK. Diabeticheskaya nefropatiya. Zavisit li renoprotekciya ot vybora saharosnizhayushchej terapii. Medicinskij sovet 2015; (7): 32-43]
11. Kalra S, Singh V, Nagrale D. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review. Adv Ther 2016; 33(9):1502-1518
Review
For citations:
Okovity`i` S.V., Beresneva O.N., Parastaeva M.M., Ivanova G.T., Ivkin D.Yu., Ivkina A.S., Sipovskii V.G., Zaraiyskii` M.I., Karpov A.A., Kucher А.G., Bogdanova E.O., Sipovskaya E.B., Kulikov A.N., Kayukov I.G. EMPAGLIFLOZIN RENAL SAFETY IN NORMOGLYCEMIC RATS WITH HEART FAILURE. Nephrology (Saint-Petersburg). 2018;22(1):83-90. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-1-83-90
Views:
1068
Email this article 